CRVS - Corvus

-

$undefined

N/A

(N/A)

Corvus NASDAQ:CRVS Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus' lead product candidate is CPI-006, a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells in preclinical studies. CPI-006 is being evaluated in a Phase 3 clinical trial for the treatment of hospitalized patients with COVID-19 and in a multicenter Phase 1/1b oncology clinical trial as a single agent, in combination with ciforadenant and pembrolizumab. The Company's second clinical program, CPI-818, is an investigational, oral, small molecule drug that selectively inhibited ITK in preclinical studies, and is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. Its third clinical program, ciforadenant (CPI-444), is an oral, small molecule inhibitor of the A2A receptor.

Location: 863 Mitten Rd Ste 102, California, 94010-1311, US | Website: www.corvuspharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

143.3M

Cash

51.96M

Avg Qtr Burn

-6.356M

Short % of Float

10.31%

Insider Ownership

3.25%

Institutional Own.

55.43%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Soquelitinib (CPI-818) Details
Cancer, Blood cancer, Peripheral T-cell Lymphomas

Phase 3

Data readout

Soquelitinib Details
Autoimmune Lymphoproliferative Syndrome

Phase 2

Data readout

Mupadolimab (CPI-006) Details
Cancer, Lung cancer, Renal cell carcinoma, Non-small cell lung carcinoma

Phase 2

Update

Soquelitinib (CPI-818) Details
Cancer, Renal cell carcinoma (renal cell cancer)

Phase 2

Initiation

Ciforadenant +/- ipilimumab and nivolumab Details
Cancer, 1L metastatic renal cell carcinoma (renal cell cancer)

Phase 1/2

Data readout

Mupadolimab + pembrolizumab Details
Cancer, Head and neck cancer, Non-small cell lung carcinoma

Phase 1

Data readout

Soquelitinib (CPI-818) Details
Skin disease/disorder, Atopic dermatitis

Phase 1

Data readout

Failed

Discontinued